Skip to main content
. 2017 Aug 5;104(5):407–415. doi: 10.1136/heartjnl-2017-311652

Figure 3.

Figure 3

Pooled and individual estimates of relative risk (RR) and 95% CIs of the secondary outcome cardiovascular mortality for different therapies. Data are shown stratified by individual class blockers (beta-blockers, ACE inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists and other drug classes). Random-effects model used.